Literature DB >> 12121899

Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.

Ignatius W Fong1, Brian Chiu, Esther Viira, Dan Jang, James B Mahony.   

Abstract

Chlamydia pneumoniae may play a role in atherogenesis and vascular diseases, and antibiotics may prove useful in these conditions. Three groups of New Zealand White rabbits (24 per group) were infected via the nasopharynx with C. pneumoniae on three separate occasions (2 weeks apart). Group I was untreated and sacrificed at 12 weeks; group II received clarithromycin at 20 mg/kg/day for 8 days, beginning 5 days after each inoculation (early treatment); and group III received a similar dose of clarithromycin starting 2 weeks after the third inoculation and continued for 6 weeks thereafter (delayed treatment). To test for a possible anti-inflammatory effect of clarithromycin, two other groups of uninfected rabbits (12 animals in each) were fed 0.5% cholesterol-enriched chow, and one of these groups was treated with clarithromycin at 30 mg/kg/day for 6 weeks. Of 23 untreated infected rabbits, 8 developed early lesions of atherosclerosis, whereas 2 of the 24 early-treated group II had similar changes (P = 0.036 [75% efficacy]). However, in the delayed-treatment group, group III, 3 of 24 rabbits developed early lesions of atherosclerosis, thus demonstrating 62.5% reduction compared to the untreated controls (P = 0.07 [trend to statistical significance]). C. pneumoniae antigen was detected in 8 of 23 group I (untreated) rabbits versus 1 of 24 of the early-treated (group II) rabbits and 4 of 24 animals in the delayed group III (P = 0.009 and 0.138, respectively). All of the untreated, cholesterol-fed rabbits had moderate to advanced atherosclerosis (grade III or IV); clarithromycin had no effect on reducing the prevalence of but did reduce the extent of atherosclerosis in the cholesterol-fed rabbits by 17% compared to untreated controls. Thus, clarithromycin administration modified C. pneumoniae-induced atherosclerotic lesions and reduced the ability to detect organism in tissue. Early treatment was more effective than delayed treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121899      PMCID: PMC127348          DOI: 10.1128/AAC.46.8.2321-2326.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Chronic infections and coronary heart disease: is there a link?

Authors:  J Danesh; R Collins; R Peto
Journal:  Lancet       Date:  1997-08-09       Impact factor: 79.321

2.  Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin.

Authors:  F Scaglione; G Rossoni
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

3.  Rabbit model for Chlamydia pneumoniae infection.

Authors:  I W Fong; B Chiu; E Viira; M W Fong; D Jang; J Mahony
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

4.  Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  T C Moazed; L A Campbell; M E Rosenfeld; J T Grayston; C C Kuo
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

5.  Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.

Authors:  F Blasi; F Denti; M Erba; R Cosentini; R Raccanelli; A Rinaldi; L Fagetti; G Esposito; U Ruberti; L Allegra
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

6.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.

Authors:  J B Muhlestein; J L Anderson; E H Hammond; L Zhao; S Trehan; E P Schwobe; J F Carlquist
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

7.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.

Authors:  K Laitinen; A Laurila; L Pyhälä; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

8.  The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae.

Authors:  H Hu; G N Pierce; G Zhong
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

9.  Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery.

Authors:  B Chiu; E Viira; W Tucker; I W Fong
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

10.  Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.

Authors:  M Maass; C Bartels; P M Engel; U Mamat; H H Sievers
Journal:  J Am Coll Cardiol       Date:  1998-03-15       Impact factor: 24.094

View more
  8 in total

1.  Heat-inactivated C. pneumoniae organisms are not atherogenic.

Authors:  Jyotika Sharma; Yuhong Niu; Jianbo Ge; Grant N Pierce; Guangming Zhong
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

Review 2.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

Review 3.  Infection and Atherosclerosis Development.

Authors:  Lee Ann Campbell; Michael E Rosenfeld
Journal:  Arch Med Res       Date:  2015-05-21       Impact factor: 2.235

Review 4.  Helicobacter pylori infection and atherosclerosis: is there a causal relationship?

Authors:  Z Xu; J Li; H Wang; G Xu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-27       Impact factor: 3.267

5.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Biophysical and Biochemical Outcomes of Chlamydia pneumoniae Infection Promotes Pro-atherogenic Matrix Microenvironment.

Authors:  Shankar J Evani; Shatha F Dallo; Anand K Ramasubramanian
Journal:  Front Microbiol       Date:  2016-08-17       Impact factor: 5.640

7.  A biomathematical model of atherosclerosis in mice.

Authors:  Sibylle Schirm; Arash Haghikia; Markus Brack; Peter Ahnert; Geraldine Nouailles; Norbert Suttorp; Markus Loeffler; Martin Witzenrath; Markus Scholz
Journal:  PLoS One       Date:  2022-08-03       Impact factor: 3.752

8.  Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical options.

Authors:  Mohammed Abdalla Abbas; Albrecht Guenther; Sebastiano Galantucci; Gharib Fawi; Giancarlo Comi; Joseph Kwan; Francesco Corea
Journal:  Open Neurol J       Date:  2008-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.